Efficacy and safety of esmirtazapine in adult outpatients with chronic primary insomnia: a randomized, double-blind placebo-controlled study and open-label extension

STUDY OBJECTIVES: Esmirtazapine (1.5–4.5 mg) has demonstrated short-term sleep-promoting effects in nonelderly outpatients with chronic insomnia. This phase 3, randomized, double-blind study (NCT00631657) and its open-label extension (NCT00750919) investigated efficacy and safety of long-term esmirt...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Sleep Med
Main Authors: Ivgy-May, Neely, Hajak, Goeran, van Osta, Gonnie, Braat, Sabine, Chang, Qing, Roth, Thomas
Formato: Artigo
Idioma:Inglês
Publicado em: American Academy of Sleep Medicine 2020
Assuntos:
Scientific Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7970588/
https://ncbi.nlm.nih.gov/pubmed/32351205
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5664/jcsm.8526
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados